Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Parkinson's disease is a relentlessly progressive neurodegenerative disease. Breakdown of compensatory mechanisms influencing putaminal dopamine processing could contribute to the progressive motor symptoms. We studied a cohort of 78 subjects (at baseline) with sporadic Parkinson's disease and 35 healthy controls with multi-tracer positron emission tomography scans to investigate the evolution of adaptive mechanisms influencing striatal dopamine processing in Parkinson's disease progression. Presynaptic dopaminergic integrity was assessed with three radioligands: (i) [(11)C](±)dihydrotetrabenazine, to estimate the density of vesicular monoamine transporter type 2; (ii) [(11)C]d-threo-methylphenidate, to label the dopamine transporter; and (iii) 6-[(18)F]fluoro-L-DOPA, to assess the activity of aromatic amino acid decarboxylase and storage of 6-[(18)F]-fluorodopamine in synaptic vesicles. The subjects with Parkinson's disease and the healthy controls underwent positron emission tomography scans at the initial visit and after 4 and 8 years of follow-up. Non-linear multivariate regression analyses with random effects were utilized to model the longitudinal changes in tracer values in the putamen standardized relative to normal controls. We found evidence for possible upregulation of dopamine synthesis and downregulation of dopamine transporter in the more severely affected putamen in the early stage of Parkinson's disease. The standardized 6-[(18)F]fluoro-L-DOPA and [(11)C]d-threo-methylphenidate values tended to approach [(11)C](±)dihydrotetrabenazine values in the putamen in later stages of disease (i.e. for [(11)C](±)dihydrotetrabenazine values <25% of normal), when the rates of decline in the positron emission tomography measurements were similar for all the markers. Our data suggest that compensatory mechanisms decline as Parkinson's disease progresses. This breakdown of compensatory strategies in the putamen could contribute to the progression of motor symptoms in advanced disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Clinical progression in Parkinson disease and the neurobiology of axons
Cheng, H., Ulane, C. M., & Burke, R. E. (2010) · Annals of Neurology · doi:10.1002/ana.21995 · Cited by 1,012
A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis
Perez, R. G., Waymire, J. C., Lin, E., Liu, J. J., Guo, F., & Zigmond, M. J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03090.2002 · Cited by 598
Age‐specific progression of nigrostriatal dysfunction in Parkinson's disease
de la Fuente‐Fernández, R., Schulzer, M., Kuramoto, L., Cragg, J., Ramachandiran, N., Au, W. L., Mak, E., McKenzie, J., McCormick, S., Sossi, V., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22284 · Cited by 222
Self-citationAlerte, T. N. M., Akinfolarin, A. A., Friedrich, E. E., Mader, S. A., Hong, C.-S., & Perez, R. G. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.02.014 · Cited by 98 · cited 1×
“VMAT2, dopamine transporter, tyrosine hydroxylase and aromatic amino acid decarboxylase have been recognized as key players in Parkinson’s disease pathogenesis (Miller et al., 1997; Lotharius et al., 2002; Perez et al. 2002; Wersinger et al., 2003; Tehranian et al., 2006; Alerte et al., 2008; Liu et al., 2008; Afonso-…”
Background
Cited by
Calabresi, P., Mechelli, A., Natale, G., Volpicelli-Daley, L., Di Lazzaro, G., & Ghiglieri, V. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-05672-9 · Cited by 817
Blesa, J., Trigo-Damas, I., Dileone, M., del Rey, N. L.-G., Hernandez, L. F., & Obeso, J. A. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.002 · Cited by 256
Metadata
- Authors
- Nandhagopal, R., Kuramoto, L., Schulzer, M., Mak, E., Cragg, J., McKenzie, J., McCormick, S., Ruth, T. J., Sossi, V., de la Fuente-Fernandez, R., & Stoessl, A. J.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-11
- Volume
- 134
- Issue
- 11
- Pages
- 3290-3298
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2335662141
- Cited by
- 167
- References
- 6
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.